ARPA-H announced THRIVE, a program funding up to $160 million to advance bespoke gene-editing therapies for rare diseases into the clinic. The effort includes seven teams pursuing different rare genetic pediatric conditions and aims to start clinical trials by year three for program teams. The initiative is framed as a multi-approach push—spanning different technological and trial-design strategies—while focusing on acceleration of translational readiness for rare disease therapies. Sponsors will be expected to meet time-bound clinical milestones, increasing competitive pressure on preclinical-to-IND execution. For biotech investors, THRIVE is a signal that U.S. government funding is prioritizing not just early science, but speed to first-in-human studies.